A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

NCT02532855 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

614

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Sitagliptin
DRUG: Dapagliflozin
DRUG: Metformin
DRUG: Matching placebo to sitagliptin
DRUG: Matching placebo to dapagliflozin
DRUG: Sulfonylurea

Sponsor

Merck Sharp & Dohme LLC